Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Odri, Guillaume ^a,b,c   Kim, Pui Pui ^a,b   Lamoureux, François ^a,b   Charrier, Céline ^a,b   Battaglia, Séverine ^a,b   Amiaud, Jérôme ^a,b   Heymann, Dominique ^a,b   Gouin, François ^a,b,c   Redini, Françoise ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

Author keywords

Animal models; Ewing's sarcoma; Lung metastases; Zoledronic acid

Indexed keywords

GELATINASE A; GELATINASE B; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; TIBIA; TUMOR INVASION; ANIMAL; BONE NEOPLASMS; CELL MOTION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SARCOMA, EWING; SECONDARY; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; SARCOMA, EWING; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84897551199     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-169     Document Type: Article

References (29)

1. Esiashvili N, Goodman M, Marcus RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and End results data. J Pediatr Hematol Oncol 2008, 30(6):425-430. 10.1097/MPH.0b013e31816e22f3, 18525458.
2. Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir G. [Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma]. C R Seances Acad Sci III 1983, 296(23):1101-1103.
3. Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F, Manning J, Neff J, Reinus W, Shuster JJ TE. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998, 42(1):125-135.
4. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000, 18(17):3108-3114.
5. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997, 33(7):1061-1069. 10.1016/S0959-8049(97)00043-9, 9376188.
6. Jenkin RD, Al-Fawaz I, Al-Shabanah MO, Allam A, Ayas M, Memon M, Rifai S, Schultz HP. Metastatic Ewing sarcoma/PNET of bone at diagnosis: prognostic factors-a report from Saudi Arabia. Med Pediatr Oncol 2001, 37(4):383-389. 10.1002/mpo.1214, 11568903.
7. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001, 19(11):2812-2820.
8. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Frohlich B, Winkelmann W, Zoubek A, Jurgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998, 9(3):275-281. 10.1023/A:1008208511815, 9602261.
9. Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, Schwartz GK, Bonilla MA, Lindsley KL, Merchant TE, Rosenfield NS, Abramson SJ, Cheung N-KV. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995, 13(11):2796-2804.
10. Dahlin DC, Coventry MB, Scanlon PW. Ewing's Sarcoma: a critical analysis of 165 cases. J Bone Joint Surg Am 1961, 43(2):185-192.
11. Schleiermacher G, Peter M, Oberlin O, Philip T, Rubie H, Mechinaud F, Sommelet-Olive D, Landman-Parker J, Bours D, Michon J, Delattre O, . Société Française d'Oncologie Pédiatrique Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003, 21(1):85-91. 10.1200/JCO.2003.03.006, 12506175, Société Française d'Oncologie Pédiatrique.
12. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19(3):281-290. 10.1016/8756-3282(96)00182-2, 8873969.
13. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88(6):2095-2105. 10.1172/JCI115539, 295810, 1661297.
14. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005, 37(1):74-86. 10.1016/j.bone.2005.02.020, 15894525.
15. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008, 98(11):1736-1740. 10.1038/sj.bjc.6604382, 2410129, 18506174.
16. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104(11):2522-2529. 10.1002/cncr.21530, 16270320.
17. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004, 10(7):337-343. 10.1016/j.molmed.2004.05.007, 15242682.
18. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Rédini F. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010, 70(19):7610-7619. 10.1158/0008-5472.CAN-09-4272, 20841471.
19. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother 2007, 30(4):370-377. 10.1097/CJI.0b013e31802bff16, 17457212.
20. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterlüty H, Scotlandi K, Kotz R, Micksche M, Berger W. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006, 24(6):1145-1152. 10.1002/jor.20129, 16602111.
21. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60(11):2949-2954.
22. Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis 2011, 17(2):194-199. 10.1111/j.1601-0825.2010.01720.x, 20796232.
23. Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 2009, 602(1):124-131. 10.1016/j.ejphar.2008.10.043, 19000670.
24. Scotlandi K, Benini S, Manara MC, Serra M, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Chano T, Picci P, Baldini N. Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res 2000, 18(6):959-966. 10.1002/jor.1100180616, 11192257.
25. Wolfe TD, Pillai SP, Hildreth BE, Lanigan LG, Martin CK, Werbeck JL, Rosol TJ. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clin Exp Metastasis 2011, 28(4):377-389. 10.1007/s10585-011-9377-9, 21374084.
26. Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A, Sommerville S, Dickinson I, Guminski A, Saunders NA. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res 2010, 70(18):7063-7072. 10.1158/0008-5472.CAN-09-4291, 20823153.
27. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4 T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10(13):4559-4567. 10.1158/1078-0432.CCR-03-0325, 15240548.
28. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC. The EWS/FLI oncogene drives changes in cellular morphology, adhesion, and migration in Ewing sarcoma. Genes Cancer 2012, 3(2):102-116. 10.1177/1947601912457024, 3463921, 23050043.
29. Strauss SJ, Ng T, Mendoza-Naranjo A, Whelan J, Sorensen PH. Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist 2010, 15(6):627-635. 10.1634/theoncologist.2010-0093, 3227993, 20479280.